On the occasion of the Grenoble EuroMedtech meeting that took place between May 31st and June 1st 2012, Françoise Cailler, SurgiMab’s president, answered BioPharmInsight‘s questions (the Financial Times group). She describes the next steps for SurgiMab in terms of development.
